Overview An Open-Label Study of DCCR Tablet in Patients With PWS Status: Withdrawn Trial end date: 2019-10-01 Target enrollment: Participant gender: Summary The primary objective of this study is to monitor the long-term safety of DCCR in PWS patients. Phase: Phase 3 Details Lead Sponsor: Soleno Therapeutics, Inc.